Novel Indolopyridines, Benzofuranopyridines and Benzothienopyridines
Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and X have the meanings indicated in the description, are novel effective compounds with anti-proliferative and/or apoptosis inducing activity.
1 . A compound of formula I
in which
R1 is 1-4C-alkyl, 3-7C-cycloalkyl, or 3-7C-cycloalkyl-14C-alkyl,
R2 is hydrogen, 1-4C-alkyl, halogen, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, hydroxy-2-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkyl-1-4C-alkoxy, or completely or predominantly fluorine-substituted 1-4C-alkoxy,
R3 is completely or predominantly fluorine-substituted 14C-alkoxy, 1-4C-alkoxycarbonyl or carboxyl,
R4 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,
X is NH, oxygen or sulphur,
R5 is hydrogen, hydroxyl, 1-4C-alkyl, halogen, trifluoromethyl, or 1-4C-alkoxy,
R6 is hydrogen, halogen, or 1-4C-alkyl,
or a salt, stereoisomer or a salt of a stereoisomer thereof.
2 . A compound according to claim 1 , which is from formula Ia*
in which
R1 is methyl or ethyl,
R2 is hydrogen, methyl, chlorine, fluorine, trifluoromethyl, methoxy or difluoromethoxy,
R3 is completely or predominantly fluorine-substituted 1-2C-alkoxy,
R4 is hydrogen,
X is NH, oxygen or sulphur,
R5 is bonded to the 5- or 7-position of the scaffold, and is hydrogen, methyl, chlorine, fluorine or trifluoromethyl,
R6 is hydrogen,
or a salt thereof.
3 . A compound according to claim 1 , which is from formula Ia*,
in which
R1 is ethyl,
R2 is hydrogen, methyl, chlorine, fluorine or methoxy,
R3 is difluoromethoxy or trifluoromethoxy,
R4 is hydrogen,
X is NH, oxygen or sulphur,
R5 is bonded to the 5- or 7-position of the scaffold, and is hydrogen, methyl or fluorine,
R6 is hydrogen,
or a salt thereof.
4 . A compound according to claim 1 , which is from formula Ia*,
in which
R1 is methyl,
R2 is hydrogen, methyl, chlorine, fluorine or methoxy,
R3 is a difluoromethoxy or trifluoromethoxy,
R4 is hydrogen,
X is NH,
R5 is hydrogen,
R6 is hydrogen,
or a salt thereof.
5 . A compound according to claim 1 , which
in which
R1 is methyl or ethyl,
R2 is hydrogen, methyl, chlorine, fluorine, trifluoromethyl, methoxy or difluoromethoxy,
R3 is methoxycarbonyl or ethoxycarbonyl,
R4 is hydrogen,
X is NH, oxygen or sulphur,
R5 is bonded to the 5- or 7-position of the scaffold, and is hydrogen, methyl, chlorine, fluorine or trifluoromethyl,
R6 is hydrogen,
or a salt thereof.
6 . A compound according to claim 1 , which is from formula Ia* or Ib*,
in which
R1 is methyl,
R2 is hydrogen, methyl, chlorine, fluorine or methoxy,
R3 is methoxycarbonyl,
R4 is hydrogen,
X is NH, oxygen or sulphur,
R5 is bonded to the 5- or 7-position of the scaffold, and is hydrogen, methyl or fluorine,
R6 is hydrogen,
or a salt thereof.
7 . A compound according to claim 1 , which is from formula Ia* or Ib*,
in which
R1 is methyl,
R2 is hydrogen, methyl, chlorine, fluorine or methoxy,
R3 is methoxycarbonyl,
R4 is hydrogen,
X is NH,
R5 is hydrogen,
R6 is hydrogen,
or a salt thereof.
8 . A compound of formula I according to claim 1 ,
in which
R1 is 1-4C-alkyl, 3-7C-cycloalkyl, or 3-7C-cycloalkyl-1-4C-alkyl,
R2 is hydrogen, 1-4C-alkyl, halogen, trifluoromethyl, 1-4C-alkoxy, 14C-alkoxy-2-4C-alkoxy, hydroxy-2-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkyl-1-4C-alkoxy, or completely or predominantly fluorine-substituted 1-4C-alkoxy,
R3 is completely or predominantly fluorine-substituted 1-4C-alkoxy,
R4 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,
X is NH, oxygen or sulphur,
R5 is hydrogen, hydroxyl, 1-4C-alkyl, halogen, or 1-4C-alkoxy,
R6 is hydrogen, halogen, or 1-4C-alkyl,
or a salt, stereoisomer or a salt of a stereoisomer thereof.
9 . A compound according to claim 1 , which is from formula Ia*,
in which
R1 is methyl, or ethyl,
R2 is hydrogen, or 1-4C-alkoxy,
R3 is completely or predominantly fluorine-substituted 1-4C-alkoxy,
R4 is hydrogen,
X is NH, oxygen or sulphur,
R5 is hydrogen,
R6 is hydrogen,
or a salt thereof.
10 . A compound according to claim 1 , which is from formula Ia*,
comprising one or more of the following:
R1 is methyl;
R2 is hydrogen or methoxy;
R3 is trifluoromethoxy or difluoromethoxy;
R4 is hydrogen; and
R5 and R6 are both hydrogen;
or a salt thereof.
11 . A compound according to claim 1 , which is from formula Ia*,
in which
R4 is hydrogen, and
R2 and X have any of the following meanings:
X
R2
1.)
NH
Methoxy
2.)
O
Methoxy
3.)
S
methoxy
4.)
NH
chlorine
5.)
O
chlorine
6.)
S
chlorine
7.)
NH
fluorine
8.)
O
fluorine
9.)
S
fluorine
10.)
NH
methyl
11.)
O
methyl
12.)
S
methyl
13.)
NH
hydrogen
14.)
O
hydrogen
15.)
S
hydrogen
or a salt thereof.
12 . A compound of formula I according to claim 1 , which is selected from the group consisting of
(3aS,10R)-2-Methyl-1-thioxo-10-(3-trifluoromethoxy-phenyl)-1,2,3a,4,9,10-hexahydro-2,9,10a-triaza-cyclopenta[b]fluoren-3-one,
(3aS,10R)-10-[3-(1,1-Difluoro-methoxy)-phenyl]-2-methyl-1-thioxo-1,2,3a,4,9,10-hexahydro-2,9,10a-triaza-cyclopenta[b]fluoren-3-one,
(3aS,10R)-10-[3,5-Bis-(1,1-difluoro-methoxy)-phenyl]-2-methyl-1-thioxo-1,2,3a,4,9,10-hexahydro-2,9,10a-triaza-cyclopenta[b]fluoren-3-one,
3-((3aS,10R)-2-Methyl-3-oxo-1-thioxo-2,3,3a,4,9,10-hexahydro-1H-2,9,10a-triaza-cyclopenta[b]fluoren-10-yl)-benzoic acid methyl ester,
3-Chloro-5-((3aS,10R)-2-methyl-3-oxo-1-thioxo-2,3,3a,4,9,10-hexahydro-1H-2,9,10a-triaza-cyclopenta[b]fluoren-10-yl)-benzoic acid methyl ester,
4-Methoxy-3-((3aS,10R)-2-methyl-3-oxo-1-thioxo-2,3,3a,4,9,10-hexahydro-1H-2,9,10a-triaza-cyclopenta[b]fluoren-10-yl)-benzoic acid methyl ester, and salts thereof.
13 . (canceled)
14 . A pharmaceutical composition comprising one or more compounds according to claim 1 , or a pharmaceutically acceptable salt, stereoisomer or salt of a stereoisomer thereof, together with a pharmaceutically acceptable auxiliary and/or excipient.
15 . (canceled)
16 . A method for treating, preventing or ameliorating (hyper)proliferative diseases and/or disorders responsive to induction of apoptosis in a mammal comprising administering a therapeutically effective and tolerable amount of one or more compounds according to claim 1 , or a pharmaceutically acceptable salt, stereoisomer or salt of a stereoisomer thereof to said mammal in need thereof.
17 . A combination comprising
a first active ingredient, which is at least one compound according to claim 1 , or a pharmaceutically acceptable salt, stereoisomer or salt of a stereoisomer thereof, and
a second active ingredient, which is at least one anti-cancer agent selected from the group consisting of chemotherapeutic anti-cancer agents and target-specific anti-cancer agents,
for separate, sequential, simultaneous, concurrent or chronologically staggered use in therapy.
18 . A method for treating, preventing or ameliorating hyperproliferative diseases and/or disorders responsive to induction of apoptosis in a patient comprising administering separately, simultaneously, concurrently, sequentially or chronologically staggered to said patient in need thereof,
an amount of a first active compound, which is a compound according to claim 1 , or a pharmaceutically acceptable salt, stereoisomer or salt of a stereoisomer thereof, and
an amount of at least one second active compound, said second active compound being an anti-cancer agent selected from the group consisting of chemotherapeutic anti-cancer agents and target-specific anti-cancer agents, wherein the amounts of the first active compound and said second active compound result in a therapeutic effect.
19 . The combination or method according to claim 17 , in which said chemotherapeutic anti-cancer agents are selected from the group consisting of (i) alkylating/carbamylating agents; (ii) platinum derivatives; (iii) antimitotic agents/tubulin inhibitors; (iv) topoisomerase inhibitors; (v) pyrimidine antagonists; (vi) purin antagonists; and (vii) folic acid antagonists.
20 . The combination according to claim 17 , in which said target-specific anti-cancer agents are selected from (i) kinase inhibitors; (ii) proteasome inhibitors; (iii) histone deacetylase inhibitors; (iv) heat shock protein 90 inhibitors; (v) vascular targeting agents (VAT); (vi) monoclonal antibodies; (vii) oligonucleotide based therapeutics; (viii) Toll-like receptor/TLR 9 agonists; (x) hormonal therapeutics;
(xi) bleomycin; (xii) retinoids; (xiii) DNA methyltransferase inhibitors; (xiv) alanosine; (xv) cytokines; and (xvi) death receptor agonists.
21 . The combination according to claim 17 , in which said cancer is selected from the group consisting of
cancer of the breast, bladder, bone, brain, central and peripheral nervous system, colon, endocrine glands, esophagus, endometrium, germ cells, head and neck, kidney, liver, lung, larynx and hypopharynx, mesothelioma, sarcoma, ovary, pancreas, prostate, rectum, renal, small intestine, soft tissue, testis, stomach, skin, ureter, vagina and vulva; inherited cancers, retinomblastoma and Wilms tumor; leukemia, lymphoma, non-Hodgkins disease, chronic and acute myeloid leukaemia, acute lymphoblastic leukemia, Hodgkins disease, multiple myeloma and T-cell lymphoma; myelodysplastic syndrome, plasma cell neoplasia, paraneoplastic syndromes, cancers of unknown primary site and AIDS related malignancies.